Vincenzo Savarino

List of Publications by Year
in descending order

165 papers	6,765 citations	71102 41 h-index	71685 76 g-index
165 all docs	165 docs citations	165 times ranked	4792 citing authors

#	Article	IF	Citations
1	Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials. Digestive and Liver Disease, 2023, 55, 208-222.	0.9	10
2	Artificial Intelligence in the Diagnosis of Upper Gastrointestinal Diseases. Journal of Clinical Gastroenterology, 2022, 56, 23-35.	2.2	22
3	Gastroesophageal reflux disease: key messages for clinicians. Minerva Gastroenterology, 2022, 67, .	0.5	4
4	Toward a potential association between eosinophilic esophagitis and Klinefelter syndrome: a case series and review of the literature. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210768.	3.2	1
5	Pharmacotherapies in eosinophilic esophagitis: state of the art. Minerva Gastroenterology, 2022, 68, 69-76.	0.5	0
6	Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis. Neurogastroenterology and Motility, 2022, 34, e14416.	3.0	1
7	Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogastric junction outflow obstruction. Alimentary Pharmacology and Therapeutics, 2022, 56, 606-613.	3.7	16
8	Clinical use of mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index for the diagnosis of gastro-esophageal reflux disease. Esophagus, 2022, 19, 525-534.	1.9	11
9	Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis. Current Opinion in Pharmacology, 2022, 65, 102264.	3.5	4
10	Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1554-1563.	4.4	34
11	Management of Osteoarthritis: Expert Opinion on NSAIDs. Pain and Therapy, 2021, 10, 783-808.	3.2	40
12	Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Design, Development and Therapy, 2021, Volume 15, 1609-1621.	4.3	21
13	Prevention Strategies for Esophageal Cancerâ€"An Expert Review. Cancers, 2021, 13, 2183.	3.7	19
14	Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. Nutrients, 2021, 13, 1630.	4.1	21
15	Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence. Cancers, 2021, 13, 3162.	3.7	35
16	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Review of Gastroenterology and Hepatology, 2021, , 1-10.	3.0	4
17	Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482098086.	3.2	40
18	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. Minerva Gastroenterology, 2021, , .	0.5	5

#	Article	IF	Citations
19	Esophageal High-Resolution Manometry Can Unravel the Mechanisms by Which Different Bariatric Techniques Produce Different Reflux Exposures. Journal of Gastrointestinal Surgery, 2020, 24, 1-7.	1.7	37
20	Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. Digestive Diseases and Sciences, 2020, 65, 2397-2402.	2.3	6
21	A further step forward in our knowledge of the pathogenetic role of gastroesophageal reflux in pulmonary fibrosis. Digestive and Liver Disease, 2020, 52, 986-987.	0.9	1
22	Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2790-2792.e1.	3.8	9
23	Esophageal reflux hypersensitivity: Non-GERD or still GERD?. Digestive and Liver Disease, 2020, 52, 1413-1420.	0.9	16
24	Latest insights into the hot question of proton pump inhibitor safety â€“ a narrative review. Digestive and Liver Disease, 2020, 52, 842-852.	0.9	25
25	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Digestive and Liver Disease, 2020, 52, 862-868.	0.9	11
26	A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. Digestive and Liver Disease, 2020, 52, 966-980.	0.9	27
27	Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak. Journal of Clinical Medicine, 2020, 9, 2011.	2.4	16
28	The Lyon Consensus: Does It Differ From the Previous Ones?. Journal of Neurogastroenterology and Motility, 2020, 26, 311-321.	2.4	26
29	Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance. Neurogastroenterology and Motility, 2020, 32, e13919.	3.0	23
30	Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data . Clinical and Experimental Gastroenterology, 2020, Volume 13, 99-104.	2.3	14
31	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Review of Clinical Pharmacology, 2020, 13, 437-449.	3.1	21
32	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohnâ€™s Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 451-456.	0.9	21
33	Usefulness of Pep-Test for Laryngo-Pharyngeal Reflux: A Pilot Study in Primary Care. Korean Journal of Family Medicine, 2020, 41, 250-255.	1.2	7
34	Eosinophilic esophagitis and biologics. Minerva Gastroenterology, 2020, , .	0.5	1
35	Gastro-esophageal reflux disease: Key messages for clinicians. Minerva Gastroenterologica E Dietologica, 2020, , .	2.2	4
36	How to select patients for antireflux surgery? The ICARUS guidelines (international consensus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67	12.1	80

#	Article	IF	Citations
37	The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. Expert Review of Clinical Pharmacology, 2019, 12, 1011-1012.	3.1	1
38	Updates in the field of non-esophageal gastroesophageal reflux disorder. Expert Review of Gastroenterology and Hepatology, 2019, 13, 827-838.	3.0	31
39	A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. Nutrition, 2019, 67-68, 110542.	2.4	42
40	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2019, 54, 1220-1225.	1.5	6
41	Idiopathic pulmonary fibrosis and GERD: links and risks . Therapeutics and Clinical Risk Management, 2019, Volume 15, 1081-1093.	2.0	42
42	Advancements in the use of manometry and impedance testing for esophageal functional disorders. Expert Review of Gastroenterology and Hepatology, 2019, 13, 425-435.	3.0	10
43	Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohnâ€™s disease: pharmacological and clinical implications. Expert Opinion on Biological Therapy, 2019, 19, 79-88.	3.1	14
44	Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. European Journal of Clinical Investigation, 2019, 49, e13056.	3.4	30
45	Vonoprazan May Provide Better Results than PPIs in Helicobacter Pylori Eradication and Beyond â€“ Is it Time for a Change?. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 375-377.	0.9	1
46	Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn. American Journal of Gastroenterology, 2018, 113, 670-676.	0.4	60
47	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. Digestive and Liver Disease, 2018, 50, 452-456.	0.9	22
48	Psoriasis and small intestine bacterial overgrowth. International Journal of Dermatology, 2018, 57, 112-113.	1.0	21
49	Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. Seminars in Arthritis and Rheumatism, 2018, 47, 569-574.	3.4	5
50	Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. Annals of Hepatology, 2018, 17, 830-835.	1.5	25
51	Improvement in WaldenstrÃ¶mâ€™s Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. Annals of Hepatology, 2018, 17, 1072-1077.	1.5	3
52	Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Annals of Gastroenterology, 2018, 31, 639-648.	0.6	68
53	Proton pump inhibitors: use and misuse in the clinical setting. Expert Review of Clinical Pharmacology, 2018, 11, 1123-1134.	3.1	112
54	Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in nonâ€erosive reflux disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 1074-1081.	3.7	32

#	Article	IF	Citations
55	Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. Gastroenterology Research and Practice, 2018, 2018, 1-7.	1.5	17
56	Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) â€" Study section â€œDigestive Diseases in Primary Careâ€• Digestive and Liver Disease, 2018, 50, 894-902.	0.9	30
57	Highâ€resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical inÂvivo evaluation. United European Gastroenterology Journal, 2018, 6, 981-989.	3.8	55
58	A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety, 2018, 17, 785-794.	2.4	24
59	Reduction in <scp>TIMP</scp>â€2 serum levels predicts remission of inflammatory bowel diseases. European Journal of Clinical Investigation, 2018, 48, e13002.	3.4	13
60	Effects of bariatric surgery on the esophagus. Current Opinion in Gastroenterology, 2018, 34, 243-248.	2.3	12
61	The appropriate use of proton-pump inhibitors. Minerva Medica, 2018, 109, 386-399.	0.9	46
62	Improvement in WaldenstrÃ¶mâ€™s Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. Annals of Hepatology, 2018, 17, 0-10.	1.5	0
63	Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. Journal of Gastroenterology, 2017, 52, 444-451.	5.1	96
64	Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives. Digestive Diseases and Sciences, 2017, 62, 1881-1889.	2.3	66
65	A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opinion on Pharmacotherapy, 2017, 18, 1333-1343.	1.8	39
66	A Nodule, is a Nodule, is a Nodule: May Alpha-Fetoprotein Make the Difference?. American Journal of Gastroenterology, 2017, 112, 1340.	0.4	1
67	Vonoprazan fumarate for the management of acid-related diseases. Expert Opinion on Pharmacotherapy, 2017, 18, 1145-1152.	1.8	43
68	The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. European Journal of Internal Medicine, 2017, 37, 19-24.	2.2	184
69	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohnâ€™s disease. A study performed using the LÃ©mann Index. Digestive and Liver Disease, 2017, 49, 175-180.	0.9	25
70	Drugs for improving esophageal mucosa defense: where are we now and where are we going?. Annals of Gastroenterology, 2017, 30, 585-591.	0.6	26
71	Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. Annals of Gastroenterology, 2017, 31, 1-7.	0.6	28
72	Update in gastroesophageal reflux disease. Minerva Gastroenterology, 2017, 63, 172-174.	0.5	0

#	Article	IF	Citations
73	Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 2017, 23, 318-319.	2.4	1
74	Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterology, 2017, 63, 175-183.	0.5	30
75	Complexity and diversity of gastroesophageal reflux disease phenotypes. Minerva Gastroenterology, 2017, 63, 198-204.	0.5	1
76	Etiopathogenesis of rosacea: a prospective study with a three-year follow-up. Italian Journal of Dermatology and Venereology, 2017, 152, 418-423.	0.2	7
77	Barrettâ€™s esophagus in 2016: From pathophysiology to treatment. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 190.	1.1	18
78	Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis. Journal of Neurogastroenterology and Motility, 2016, 22, 710-711.	2.4	0
79	Tryciclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. American Journal of Gastroenterology, 2016, 111, 1037-1038.	0.4	1
80	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohnâ€™s disease. Scandinavian Journal of Gastroenterology, 2016, 51, 1081-1086.	1.5	36
81	956 Impairment of Chemical Clearance and Mucosal Integrity Distinguish Hypersensitive Esophagus From Functional Heartburn. Gastroenterology, 2016, 150, S189-S190.	1.3	3
82	Ilaprazole for the treatment of gastro-esophageal reflux. Expert Opinion on Pharmacotherapy, 2016, 17, 2107-2113.	1.8	13
83	Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity. Toxicology and Applied Pharmacology, 2016, 306, 113-119.	2.8	21
84	Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. Autoimmunity Reviews, 2016, 15, 1208-1209.	5.8	10
85	Fecal calprotectin in systemic sclerosis: Light and shade of a promising tool. Autoimmunity Reviews, 2016, 15, 1206-1207.	5.8	2
86	It is Time to Re-Think the Role of Small Intestinal Bacterial Overgrowth in IBS Patients. American Journal of Gastroenterology, 2016, 111, 1364.	0.4	2
87	The role of small intestinal bacterial overgrowth in rosacea: A 3-year follow-up. Journal of the American Academy of Dermatology, 2016, 75, e113-e115.	1.2	43
88	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. American Journal of Gastroenterology, 2016, 111, 1711-1717.	0.4	55
89	Practice guidelines on the use of esophageal manometry â€“ A GISMAD-SIGE-AIGO medical position statement. Digestive and Liver Disease, 2016, 48, 1124-1135.	0.9	82
90	Sequential versus standard triple first-line therapy forHelicobacter pylorieradication. The Cochrane Library, 2016, , CD009034.	2.8	35

#	Article	IF	Citations
91	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1333-1341.	3.3	17
92	Are proton pump inhibitors really so dangerous?. Digestive and Liver Disease, 2016, 48, 851-859.	0.9	66
93	Analyses of the Post-reflux Swallow-induced Peristaltic Wave Index and Nocturnal Baseline Impedance Parameters Increase the Diagnostic Yield of Impedance-pH Monitoring of Patients With Reflux Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 40-46.	4.4	222
94	Esophagogastric junction morphology assessment by high resolution manometry in obese patients candidate to bariatric surgery. International Journal of Surgery, 2016, 28, S109-S113.	2.7	21
95	Prognostic role of mean platelet volume in patients with cirrhosis. Digestive and Liver Disease, 2016, 48, 409-413.	0.9	16
96	An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic HCV infection and advanced liver disease. Gut, 2016, 65, 183-184.	12.1	0
97	Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors. World Journal of Gastrointestinal Surgery, 2016, 8, 719.	1.5	9
98	Esophageal testing: What we have so far. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 72.	1.0	26
99	Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. Journal of Neurogastroenterology and Motility, 2015, 21, 292-293.	2.4	2
100	Optimal management of constipation associated with irritable bowel syndrome. Therapeutics and Clinical Risk Management, 2015, 11, 691.	2.0	11
101	Hepatocellular Carcinoma Is the Most Frequent Final Diagnosis of Focal Liver Lesions Identified in a Cross-Sectional Evaluation of Patients with Chronic Liver Disease in Saudi Arabia. Journal of Cancer Research, 2015, 2015, 1-4.	0.7	1
102	Antiâ€“Tumor Necrosis Factor Antibodies for Prevention of Crohnâ€™s Disease Recurrence After Surgery: More Than a Hope. Clinical Gastroenterology and Hepatology, 2015, 13, 1856.	4.4	1
103	Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn. Clinical Gastroenterology and Hepatology, 2015, 13, 1082-1088.e1.	4.4	121
104	Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice. American Journal of Gastroenterology, 2015, 110, 472-473.	0.4	6
105	Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring. Digestive and Liver Disease, 2015, 47, 1027-1032.	0.9	12
106	Starry Liver: An Unexpected Diagnosis. ACG Case Reports Journal, 2015, 2, 77-78.	0.4	3
107	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. Journal of Neurogastroenterology and Motility, 2014, 20, 129-130.	2.4	2
108	Esophageal motility abnormalities in gastroesophageal reflux disease. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2014, 5, 86.	1.1	68

#	Article	IF	Citations
109	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. Digestive and Liver Disease, 2014, 46, 1043-1046.	0.9	17
110	Gastrointestinal involvement in systemic sclerosis. Presse Medicale, 2014, 43, e279-e291.	1.9	59
111	The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. Journal of Gastroenterology, 2014, 49, 1362-1363.	5.1	1
112	Eosinophilic oesophagitis: From physiopathology to treatment. Digestive and Liver Disease, 2013, 45, 871-878.	0.9	25
113	The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1361-1369.	3.3	30
114	The importance of subgrouping refractory NERD patients according to esophageal pH-impedance testing. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 3503-3504.	2.4	0
115	Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. Journal of Gastroenterology, 2013, 48, 473-482.	5.1	157
116	Functional testing: pharyngeal pH monitoring and highâ€resolution manometry. Annals of the New York Academy of Sciences, 2013, 1300, 226-235.	3.8	12
117	Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. Annals of the New York Academy of Sciences, 2013, 1300, 278-295.	3.8	17
118	NERD: an umbrella term including heterogeneous subpopulations. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 371-380.	17.8	184
119	Lactulose Breath Test to Assess Oro-cecal Transit Delay and Estimate Esophageal Dysmotility in Scleroderma Patients. Seminars in Arthritis and Rheumatism, 2013, 42, 522-529.	3.4	29
120	Endotherapy for and tailored approaches to treating GERD, and refractory GERD. Annals of the New York Academy of Sciences, 2013, 1300, 166-186.	3.8	9
121	Dysmotility and reflux disease. Current Opinion in Otolaryngology and Head and Neck Surgery, 2013, 21, 1.	1.8	21
122	Optimal treatment of laryngopharyngeal reflux disease. Therapeutic Advances in Chronic Disease, 2013, 4, 287-301.	2.5	70
123	Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease. Annals of the New York Academy of Sciences, 2013, 1300, 11-28.	3.8	6
124	Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology, 2013, 52, 1095-1100.	1.9	87
125	Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. European Respiratory Journal, 2013, 42, 1322-1331.	6.7	194
126	Therapeutic potential of curcumin in digestive diseases. World Journal of Gastroenterology, 2013, 19, 9256.	3.3	103

#	Article	IF	Citations
127	Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World Journal of Gastroenterology, 2013, 19, 5787.	3.3	46
128	Distinction between patients with non-erosive reflux disease and functional heartburn. Annals of Gastroenterology, 2013, 26, 283-289.	0.6	16
129	Alginate controls heartburn in patients with erosive and nonerosive reflux disease. World Journal of Gastroenterology, 2012, 18, 4371.	3.3	59
130	Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver International, 2012, 32, 1113-1119.	3.9	27
131	The Relevance of Weakly Acidic Reflux in Patients With Barrett's Esophagus. Gastroenterology, 2012, 143, e21-e22.	1.3	2
132	Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. Journal of Gastroenterology, 2012, 47, 159-168.	5.1	102
133	How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?. World Journal of Gastroenterology, 2012, 18, 4363.	3.3	132
134	Achalasia With Dense Eosinophilic Infiltrate Responds to Steroid Therapy. Clinical Gastroenterology and Hepatology, 2011, 9, 1104-1106.	4.4	62
135	The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 542-547.	0.9	140
136	Overweight is a risk factor for both erosive and non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 940-945.	0.9	52
137	Microscopic esophagitis and Barrett's esophagus: The histology report. Digestive and Liver Disease, 2011, 43, S319-S330.	0.9	33
138	Barrett's esophagus: proton pump inhibitors and chemoprevention II. Annals of the New York Academy of Sciences, 2011, 1232, 114-139.	3.8	12
139	Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedanceâ€“pH Off Therapy. American Journal of Gastroenterology, 2010, 105, 1053-1061.	0.4	190
140	Observational studies on prescription practices: Interpret with caution. Digestive and Liver Disease, 2010, 42, 348-349.	0.9	1
141	A Review on the Use of Eltrombopag in Patients with Advanced Liver Disease. Clinical Medicine Therapeutics, 2009, 1, CMT.S2267.	0.1	0
142	Gastroesophageal Reflux and Pulmonary Fibrosis in Scleroderma. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 408-413.	5.6	251
143	Microscopic esophagitis in gastro-esophageal reflux disease: individual lesions, biopsy sampling, and clinical correlations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 31-39.	2.8	42
144	Proton pump inhibitors in GORDAn overview of their pharmacology, efficacy and safety. Pharmacological Research, 2009, 59, 135-153.	7.1	156

#	Article	IF	Citations
145	Management Strategy for Patients With Gastroesophageal Reflux Disease: A Comparison Between Empirical Treatment With Esomeprazole and Endoscopy-Oriented Treatment. American Journal of Gastroenterology, 2008, 103, 267-275.	0.4	60
146	The Role of Nonacid Reflux in NERD: Lessons Learned From Impedance-pH Monitoring in 150 Patients off Therapy. American Journal of Gastroenterology, 2008, 103, 2685-2693.	0.4	224
147	Small Intestinal Bacterial Overgrowth in Patients Suffering From Scleroderma: Clinical Effectiveness of Its Eradication. American Journal of Gastroenterology, 2008, 103, 1257-1262.	0.4	114
148	Is acid relevant in the genesis of dyspeptic symptoms associated with nonerosive reflux disease?. European Journal of Gastroenterology and Hepatology, 2008, 20, 252-254.	1.6	3
149	Thrombocytopenia in liver disease. Current Opinion in Hematology, 2008, 15, 473-480.	2.5	81
150	Functional Heartburn and Non-Erosive Reflux Disease. Digestive Diseases, 2007, 25, 172-174.	1.9	49
151	Monitoring Cytochrome P-450 Activity During Rabeprazole Treatment in Patients with Gastresophageal Reflux Disease. Digestive Diseases and Sciences, 2006, 51, 1602-1606.	2.3	8
152	A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux Symptoms. Digestive Diseases and Sciences, 2006, 51, 1904-1909.	2.3	31
153	Proton Pump Inhibitor Failure: Why Does It Occur and How Can It Be Managed?. Digestion, 2006, 73, 215-217.	2.3	11
154	Reassessment of the Diagnostic Value of Histology in Patients with GERD, Using Multiple Biopsy Sites and an Appropriate Control Group. American Journal of Gastroenterology, 2005, 100, 2299-2306.	0.4	192
155	Optimizing Symptom Relief and Preventing Complications in Adults with Gastro-Oesophageal Reflux Disease. Digestion, 2004, 69, 9-16.	2.3	21
156	Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. Digestive Diseases and Sciences, 1998, 43, 459-463.	2.3	18
157	Increased prevalence of Helicobacter pylori infection in females treated with dopaminergic drugs for hyperprolactinaemia. Clinical Endocrinology, 1998, 48, 373-374.	2.4	2
158	Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. Journal of Hepatology, 1996, 25, 152-157.	3.7	21
159	Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointestinal Endoscopy, 1996, 44, 700-705.	1.0	135
160	A Comparison of Five Maintenance Therapies for Reflux Esophagitis. New England Journal of Medicine, 1995, 333, 1106-1110.	27.0	542
161	Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. Digestive Diseases and Sciences, 1994, 39, 1473-1482.	2.3	5
162	Variability in individual response to various doses of omeprazole. Digestive Diseases and Sciences, 1994, 39, 161-168.	2.3	38

#	Article	IF	Citations
163	Twentyâ€fourâ€Hour Control of Gastric Acidity by Twiceâ€Daily Doses of Placebo, Nizatidine 150 mg, Nizatidine 300 mg, and Ranitidine 300 mg. Journal of Clinical Pharmacology, 1993, 33, 70-74.	2.0	8
164	Duration of Acid Suppression in H₂-Antagonist Nonresponders. Digestion, 1992, 51, 185-192.	2.3	6
165	Comparison of the Effects of Placebo, Ranitidine, Famotidine and Nizatidine on Intragastric Acidity by Means of Continuous pH Recording. Digestion, 1989, 42, 1-6.	2.3	25